Abstract
Bone metastases profoundly perturb normal bone remodeling. Biochemical markers of bone turnover have been shown to reflect these tumor-induced changes in bone remodeling and might therefore be useful in the diagnosis and follow-up of patients with malignant bone disease. Most markers of bone turnover, particularly those of bone resorption, are elevated in patients with established bone metastases. While this might indicate a role for bone markers as diagnostic tools in cancer patients, the available evidence does not provide any final conclusions as to the accuracy and validity of the markers presently used in the early diagnosis of bone metastases. Markers of bone resorption respond promptly and profoundly to bisphosphonate and antineoplastic therapy, and this response is associated with a favorable clinical outcome. Most markers, however, have been more useful in groups of patients monitored in clinical studies than in studies of individuals. While this makes them a good tool for drug development, it remains unknown whether the use of bone markers in a routine clinical setting has any defined beneficial effects on overall outcome in cancer patients. In particular, no study has addressed the question of whether patients with bone metastases should be treated according to their rate of bone turnover and what the treatment goals are in this respect. While it is unlikely that bone-turnover markers have sufficient diagnostic or prognostic value when used in isolation, the combination of these markers with other diagnostic techniques might be the way forward to improve the clinical assessment of patients with cancers of the bone.
Similar content being viewed by others
References
Rubens RD (2000) Clinical aspects of bone metastases. In Tumor Bone Diseases and Osteoporosis in Cancer Patients, 85–96 (Ed Body J-J) New York: Marcel Dekker
Lipton A et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised placebo-controlled trials. Cancer 88: 1082–1090
Ross JR et al. (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327: 469–472
Bubley G et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group. J Clin Oncol 18: 3461–3477
Yoneda T and Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328: 679–687
Chung LW et al. (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10–20
Seibel MJ (2003) Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 32: 83–113
Fukumitsu N et al. (2002) Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients. Metabolism 51: 814–818
Meijer WG et al. (2003) Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44: 184–191
Ebert W et al. (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24: 3193–3201
Springer IN et al. (2003) Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples. Br J Cancer 89: 1722–1728
Francini G et al. (1990) Comparison between CEA, TPA, CA 15-3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers 5: 65–72
Berruti A et al. (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45: 1240–1247
Kanakis I et al. (2004) Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. Pharm Biomed Anal 34: 827–832
Oremek GM et al. (2003) Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res 23: 987–990
Lorente JA et al. (1999) Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26: 625–632
Wymenga LF et al. (2001) Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. Br J Urol 88: 231–235
Bombardieri E et al. (1997) Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 24: 1349–1355
Wada S et al. (1993) Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy. Int Med 32: 611–618
Bataille R et al. (1990) Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 66: 167–172
Mejjad O et al. (1996) Osteocalcin is not a marker of progress in multiple myeloma. Eur J Haematol 56: 30–34
Carlson K et al. (1999) Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62: 300–306
Berenson JR et al. (2001) A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7: 478–485
Tian E et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483–2494
Jukkola A et al. (1997) Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57: 5517–5520
Ylisirnio S et al. (1999) Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 19: 5577–5581
Koizumi M et al. (2003) Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23: 4095–4099
Paterson CR et al. (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64: 884–886
Pecherstorfer M et al. (1995) The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97–103
Alatas F et al. (2002) Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 35: 293–296
Behrens P et al. Pyridinoline cross-links as markers for primary and secondary bone tumors. Scand J Clin Lab Invest 63: 37–44
Motellon JL et al. (2000) Relationship of plasma bone cytokines with hypercalcemia in cancer patients. Clin Chim Acta 302: 59–68
Pecherstorfer M et al. (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90: 3743–3750
Ulrich U et al. (2001) Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264: 186–190
Wada N et al. (2001) Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 8: 131–137
Costa L et al. (2002) Prospective evaluation of the peptide-bound collagen type I crosslinks N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850–856
Kiuchi K et al. (2002) Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep 9: 595–598
Cloos PA et al. (2004) An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50: 279–289
Koizumi M et al. (2002) Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167: 1863–1866
Noguchi M and Noda S (2001) Pyridinoline cross-linked carboxy terminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166: 1106–1110
de la Piedra C et al. (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45–53
Nabeya Y et al. (2002) Serum cross-linked carboxy terminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 94: 940–949
Capeller B et al. (2003) Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 23: 1011–1015
Chao TY et al. (2004) Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 11: 511–516
Halleen JM et al. (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597–600
Jain A et al. (2002) Three SIBLINGs enhance Factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277: 13700–13708
Seibel MJ et al. (1996) Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81: 3289–3294
Bellahcene A et al. (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69: 350–353
Fedarko et al. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060–4066
Woitge HW et al. (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84: 344–351
Woitge HW et al. (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792–801
Brown JE et al. (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69
Vinholes J et al. (1999) Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 80: 221–228
Coleman RE et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935
Jukkola A et al. (2001) Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 21: 2873–2876
Ali SM et al. (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15: 455–459
Berruti A et al. (2002) Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers 17: 244–252
Kylmälä T et al. (1995) Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71: 1061–1064
Petrioli R et al. (2004) Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology 63: 321–326
Seibel MJ et al. (2002) Markers of bone turnover do not predict bone metastases in breast cancer. Clin Lab 48: 583–588
Seibel MJ et al. (2002) Long-term variability of markers of bone turnover in patients with breast cancer. Clin Lab 48: 576–582
De Pinieux G et al. (2001) Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J Urol 166: 1924–1930
Diel I et al. (1999) Serum bone sialoprotein in patients with primary breast cancer as a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5: 3914–3919
Fonseca R et al. (2000) Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109: 24–29
Abildgaard N et al. (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 61: 128–134
Jagdev SP et al. (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12: 1433–1438
Terpos E et al. (2000) Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 65: 331–336
Body JJ et al. (1997) Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75: 408–412
Lipton A et al. (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34: 2021–2026
Martinetti A et al. (2002) Serum levels of tartrate resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. Int J Biol Markers 17: 253–258
Carlson K et al. (1992) Serum osteocalcin concentrations in patients with multiple myeloma: correlation with disease stage and survival. J Intern Med 231: 133–137
Magnusson P et al. (1998) Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain. Clin Chem 44: 1621–1628
Koizumi M et al. (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87: 348–3451
Blomqvist C et al. (1987) The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer 60: 2907–2912
Vinholes JJ et al. (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8: 1243–1250
Luftner D et al. (2003) Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 23: 1017–1026
Chen T et al. (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228–1236
Brown JE et al. (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031–2037
Marttunen MB et al. (1999) Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int 65: 365–368
Kenny AM et al. (1995) The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80: 3287–3291
Li F et al. (1993) Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 23: 566–571
Noguchi M et al. (2003) Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61: 993–998
Diamond T et al. (1997) Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 97: 641–648
Piovesan A et al. (1997) Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease. Calcif Tissue Int 61: 362–369
Clark RE et al. (2000) Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 96: 2697–2702
Nguyen T et al. Variability of bone marker measurements. In Dynamics of Bone and Cartilage Metabolism, (Eds Seibel MJ et al.) San Diego: Elsevier/Academic, in press
Meier C et al. Monitoring of anti-resorptive treatment. In Dynamics of Bone and Cartilage Metabolism, (Eds Seibel MJ et al.) San Diego: Elsevier/Academic, in press
Delmas PD et al. (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11 (Suppl 6): S2–S17
Acknowledgements
For his support and witful company, I would like to dedicate this work to my father, Dr M Roger Seibel, PhD, on the occasion of his 80th birthday.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Seibel, M. Clinical use of markers of bone turnover in metastatic bone disease. Nat Rev Clin Oncol 2, 504–517 (2005). https://doi.org/10.1038/ncponc0320
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0320
- Springer Nature Limited
This article is cited by
-
MSTN is an important myokine for weight-bearing training to attenuate bone loss in ovariectomized rats
Journal of Physiology and Biochemistry (2022)
-
Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw
Supportive Care in Cancer (2021)
-
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer
Prostate Cancer and Prostatic Diseases (2018)
-
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
International Journal of Clinical Oncology (2017)
-
Bone remodeling markers and bone metastases: From cancer research to clinical implications
BoneKEy Reports (2015)